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Summary
The eye is a rare site for the development of malignant lym-
phoma. Based on cell type and involved intraocular struc-
tures, which as a whole represent an immune-privileged site,
several subtypes of primary intraocular lymphoma need to be
discerned. Primary vitreoretinal lymphoma (PVRL), the most
common form, is an aggressive B-cell malignancy and con-
sidered a subtype of primary central nervous system (CNS)
lymphoma. Ocular symptoms are non-specific and often
mimic uveitis, frequently resulting in delayed diagnosis.
Bilateral ocular involvement and dissemination/relapse in the
CNS are common. Diagnosis of PVRL is usually based on
the analysis of vitreous biopsy material. In addition to cyto-
logical and immunocytochemical examination, measurements
of cytokine levels and molecular determination of B-cell
clonality and recurrent mutations increase the diagnostic
yield. Both systemic chemotherapy and exclusively local
treatment, including ocular radiotherapy and intravitreal
chemotherapy, are successful approaches for the management
of PVRL, although it is currently not predictable which
patients require systemic treatment in order to avoid cerebral
dissemination, a complication associated with a considerably
worse prognosis.
Keywords: primary CNS lymphoma, intraocular lymphoma,
vitreoretinal lymphoma.
Malignant lymphomas involving the eye and surrounding
structures are rare, representing less than 10% of extran-
odal lymphoma. Due to the unique anatomical situation,
the limitations for invasive procedures and the desire to
preserve vision, both diagnosis and treatment of these
lymphomas pose specific challenges and require close
collaboration between ophthalmologists, pathologists and
oncologists.
Based on clinical and pathological features and topogra-
phy, two major groups of ocular lymphomas need to be dis-
cerned, namely: (i) lymphomas involving the ocular adnexae
and the orbit, which mainly include extranodal marginal
zone B-cell lymphoma of ‘Mucosa-Associated Lymphoid Tis-
sue’ (‘MALT’) type and involvement by different types of
systemic non-Hodgkin lymphoma (NHL); and (ii) those
affecting intraocular structures, which, for the most part, are
aggressive lymphoma entities (Coupland et al, 2004; Coup-
land & Damato, 2008). The latter group will be the subject
of this review.
Based on anatomical compartments within the eye, a num-
ber of types of primary intraocular lymphoma with distinct
distribution patterns, histology and behaviour can be dis-
cerned (Coupland & Damato, 2008; Coupland et al, 2009).
Their salient clinical and pathological features are summarized
in Table I. Secondary lymphomatous involvement of intraocu-
lar structures is less common and tends to represent a sec-
ondary manifestation of a systemic NHL, most commonly
affecting the uvea (i.e. iris, ciliary body or choroid).
The term ‘intraocular lymphoma’ was first used more than
60 years ago (Cooper & Riker, 1951; Qualman et al, 1983)
but later replaced with the now obsolete term ‘ocular reticu-
lum cell sarcoma’. Given that there are great differences in
the biology, clinical behaviour and prognosis depending on
the affected anatomical compartment of the eye and neoplas-
tic cell type, it is recommended that the vague term ‘intraoc-
ular lymphoma’ be replaced by a more specific terminology,
reflecting both the precise location and histological subtype
of lymphoma, as outlined in Table I (Coupland et al, 2009).
The most common primary intraocular lymphoma by far is
primary vitreoretinal lymphoma (PVRL), an aggressive dis-
ease classified as diffuse large B-cell lymphoma (DLBCL) and
regarded as a manifestation of primary central nervous sys-
tem lymphoma (PCNSL), reflecting the common embryolog-
ical origin of the two organs (Kluin et al, 2008). Given the
more common occurrence of PCNSL, much of the current
state of knowledge about biology and clinical behaviour of
VRL is actually inferred from the investigation of PCNSL.
This review is a critical analysis of the current state-of-the-
art knowledge and understanding of the biology of VRL, and
the recommendations for its diagnosis and treatment. This
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review also briefly discusses available literature on other lym-
phoma entities that may infiltrate the eye.
Biological and pathological features of PVRL
PVRL involving the retina, the vitreous or both structures is
by far the most common form of primary intraocular lym-
phoma. Involvement of the central nervous system (CNS) is
common, occurs in 16–34% of cases at presentation and
develops in 35–90% during the course of the disease. Con-
versely, approximately 15–25% of patients with PCNSL
develop VRL (Grimm et al, 2007, 2008). In contrast to sys-
temic DLBCL and similar to PCNSL, extracerebral dissemi-
nation is very rare. The reasons for this are unclear: some
Table I. Summary of the morphological, immunophenotypic, genotypic and clinical features known to date for the various intraocular lymphoma
subtypes.
Intraocular
Lymphoma Vitreoretinal
Uveal
Primary Secondary
Most common
WHO subtype
DLBCL EMZL Dependent on systemic
NHL (majority DLBCL)
Immunoprofile CD79a+
CD20 +
PAX5 +
BCL2 +
BCL6 + /-
MUM1/IRF4 +
CD10-/+
CD43-
IgM+
Ki67 rate: high (>80%)
CD79a+
CD20 +
PAX5 + /-
BCL2 +
BCL6-
MUM1/IRF4 + /-
CD10-
CD43 + /-
IgM+
Ki67 rate: low (5-15%)
Dependent on systemic NHL
Genotype High somatic IGH mutation load
Few on-going somatic mutations
Chromosomal translocations:
currently not known
MYD88 mutations in ~70%
Low-to-moderate somatic
IGH mutation load
Few on-going somatic
mutations
Chromosomal
abnormalities:
t(11;18)(q21;q21)
MYD88 mutations –
not known
Dependent on systemic NHL
Putative Cell
of Origin
Possibly 2 different types:
(i) Early post-germinal centre
B cell = DLBCL of ABC
type (majority)
(ii) Germinal centre cell = DLBCL
of GCB type (minority)
Post-germinal centre
(memory) B cell
Dependent on systemic NHL
Clinical
Features
Typically present in 6th and 7th decade
Symptoms:
‘Floaters’ Painless decrease in visual acuity
Signs:
Vitreous infiltrates, possibly with
subretinal involvement.
Rare involvement of choroid
Often bilateral
RPE changes on FA with ‘leopard
skin’-like alterations caused by
RPE hyper- and hypo-pigmentation.
CNS involvement (70–80% of patients)
Treatment: chemotherapy+/-radiotherapy+/-
Poor prognosis
Typically present in 4th and 5th decade
Symptoms:
Blurring of vision
Metamorphopsia
Signs:
Clear vitreous
Diffuse thickening of iris and/or choroid
Usually unilateral
Extraocular extension frequent
No CNS involvement
Treatment: low dose radiotherapy.
Good prognosis
Typically >60 years
Symptoms:
Previous history of systemic NHL
Decrease in VA
Signs:
Clear vitreous
Diffuse thickening of iris or
and/or choroid
Uni- or bilateral involvement
Concurrent secondary CNS
involvement possible
Treatment: dependent on
NHL subtype
Poor prognosis
DLBCL, diffuse large B-cell lymphoma; EMZL, extranodal marginal zone B-cell lymphoma; NHL, Non Hodgkin lymphoma; CD, cluster of differ-
entiation; ABC, activated B-cell type; GCB, germinal centre B-cell type; VA, visual acuity; RPE, retinal pigment epithelium; FA, fluorescein
angiography; WHO, World Health Organization; CNS, central nervous system.
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immunophenotypical studies have shown distinct patterns of
chemokine and chemokine receptor expression on the malig-
nant cells of PCNSL, which might explain their dissemina-
tion characteristics. Interaction of B-cell chemokines CXCL12
and CXCL13 with their receptors CXCR4 and CXCR5 medi-
ates chemotaxis and may promote B-cell survival (Chan et al,
2003; Smith et al, 2003, 2007; Montesinos-Rongen et al,
2008; Deckert et al, 2014). Elevated levels of CXCL13 in cere-
brospinal fluid (CSF) have been associated with poor prog-
nosis and may be used for diagnostic purposes (Rubenstein
et al, 2013a). However, studies confirming these site-specific
expression profiles and their potential impact on clinical
behaviour of VRL are lacking.
Furthermore, the eye, similar to the brain and the testis,
represents an immune-privileged site in which normal mech-
anisms of immune recognition of foreign antigen and
immune-mediated inflammation are inactive (Coupland
et al, 2009). The absence of local immune surveillance might
result in acquisition of distinct biological features by the neo-
plastic cells, which in turn could prevent their efficient dis-
semination to extracerebral sites. However, manifest VRL
often contains an abundance of reactive T-cells and macro-
phages, indicating that the development of clinically manifest
lymphoma is associated with a breakdown of the immune-
privileged state. Of note, PCNSL as well as DLBCL arising in
the testis, another immune-privileged site, frequently show
lack of human leucocyte antigen (HLA) class I and II expres-
sion, due to deletions of chromosome 6p2132 harbouring
the HLA locus, which may allow escape from immune attack
(Riemersma et al, 2000).
Cell of origin and immunophenotype of PVRL
The vast majority (~95%) of PVRL can be classified as
DLBCL (Fig 1); however, due to unique clinical and biologi-
cal features, PCNSL including PVRL, is recognized as a speci-
fic subtype of lymphoma in the World Health Organization
classification (Kluin et al, 2008). Primary DLBCL of the CNS
(including VRL) belong to the activated B-cell (ABC) type of
DLBCL, according to gene expression profile and mutational
status, in 80–90% of cases (Montesinos-Rongen et al, 2008).
In addition to pan-B-cell markers, such as CD20, PAX5 and
CD79a, they therefore express MUM1/IRF4, commonly BCL6
and BCL2, and usually lack CD10 and plasma cell markers,
showing that, biologically, they are arrested at a late germinal
centre B-cell differentiation stage (Coupland et al, 2005a;
Camilleri-Broet et al, 2006). VRL usually expresses mono-
typic immunoglobulin light chains and IgM or IgM and IgD
heavy chains (Coupland et al, 2009). Their proliferation and
apoptotic rate is high, also reflected in commonly high num-
bers of necrotic cells. As B-cells that have passed through the
germinal centre reaction, VRL commonly shows a high rate
of somatic mutation of the rearranged immunoglobulin
genes, in most cases without evidence for on-going hypermu-
tation and, similar to PCNSL frequently exhibit
immunoglobulin rearrangements using IGHV4-34 (Mon-
tesinos-Rongen et al, 1999; Coupland et al, 2005b; Malum-
bres et al, 2007).
Genetics of PVRL
Genetic studies of VRL are sparse, and most published data
stem from studies of PCNSL. Earlier studies of VRL using
polymerase chain reaction (PCR) have demonstrated a high
frequency of IGH/BCL2 rearrangements as a result of the
t(14;18) translocation, which occur in 85-90% of follicular
lymphoma and in about 30% of DLBCL of germinal centre
B-cell type (Chan, 2003; Wallace et al, 2006). These results,
however, are somehow at odds with the notion that most
PVRL are of ABC type, which lacks BCL2 rearrangements,
and with the fact that BCL2 translocations are rare in PCNSL
(Montesinos-Rongen et al, 2002). Translocations involving
the BCL6 oncogene occur in 17-47% of PCNSL, and activa-
tion of this master regulator of the germinal centre reaction
may be partly responsible for the arrest in the terminal B-cell
differentiation stage (Montesinos-Rongen et al, 2002; Cady
et al, 2008). Their presence in VRL has not been studied to
date. Using a high-resolution single nucleotide polymor-
phism (SNP) array for the identification of copy number
changes, large numbers of alterations with common gains on
chromosomes 1q, 18q and 19q and frequent losses on 6q,
alterations, which are also frequently identified in PCNSL,
have been demonstrated in VRL (Wang et al, 2014).
Recently, several studies using conventional techniques or
next generation sequencing have analysed the mutational
landscape of PCNSL and have identified high frequencies of
mutations in MYD88, the gene encoding Myeloid Differentia-
tion Factor 88 (MYD88), a member of the toll-like receptor
pathway, and members of the B-cell receptor signalling path-
way, including CD79B, as well as other genes resulting in a
constitutive activation of NF-kB signalling (Gonzalez-Aguilar
et al, 2012; Kraan et al, 2013; Bruno et al, 2014; Bonzheim
et al, 2015; Braggio et al, 2015; Nakamura et al, 2015). Fur-
thermore, data generated by whole exome sequencing suggest
a major impact of aberrant somatic hypermutation (SHM)
on the mutational profile of PCNSL. SHM is the process by
which mutations are introduced into the rearranged
immunoglobulin genes of germinal centre B-cells in order to
increase the binding affinity of the B-cell receptor. In addi-
tion to well-known targets, such as MYC, PAX5 and PIM1,
aberrant SHM seems to target additional genes in PCNSL,
some of which are involved in CNS development (Vater
et al, 2015).
Mutations affecting MYD88, most commonly the
canonical L265P mutation, also found in the vast majority of
lymphoplasmacytic lymphomas/Waldenstr€om macroglobuli-
naemia, and CD79B, although also present in DLBCL of
ABC type of other locations, seem to be enriched specifically
in DLBCL of immune-privileged sites, namely the testis and
the CNS. MYD88 mutations have been found in 35–79% of
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PCNSL (Montesinos-Rongen et al, 2011; Gonzalez-Aguilar
et al, 2012; Kraan et al, 2013; Braggio et al, 2015; Nakamura
et al, 2015) and were recently identified in 69% of VRL with
or without concomitant cerebral involvement (Bonzheim
et al, 2015).
Very little is known so far about epigenetic alterations and
micro-RNA (miRNA) expression profiles in PVRL, and only
few studies have addressed these topics in PCNSL (Deckert
et al, 2014). Of interest, a recent study has compared miRNA
expression profiles in vitreal aspirates of PVRL and uveitis,
and identified miR155 as consistently differentially expressed
and a potential novel biomarker (Tuo et al, 2014); however,
further validation studies are needed to confirm the value of
miRNA analysis for PVRL diagnosis.
VRL in immunosuppressed patients
Epstein-Barr virus (EBV) is identified at a very high fre-
quency in immunosuppressed patients with PCNSL, espe-
cially in the setting of acquired immunodeficiency syndrome
(AIDS) (MacMahon et al, 1991), but absent from lym-
phomas in immunocompetent patients. The same seems true
for patients with VRL, although the number of cases studied
for the presence of EBV is low (Chan, 2003).
Other types of primary and secondary intraocular
lymphoma
As outlined in Table I, primary choroidal and ciliary body
lymphoma is usually a low-grade B-cell lymphoma, and can
be subtyped as an extranodal marginal zone lymphoma;
occasionally, primary choroidal lymphomas may extend
extraocularly into the ocular adnexae, e.g. into the subcon-
junctival space (Coupland & Damato, 2008). Distinction of
primary choroidal lymphoma from PVRL is extremely
important, because the former run an indolent course and
lack any involvement of the CNS. Consequently, patients
with primary choroidal lymphoma tend to have a very good
prognosis following treatment with low-dose external beam
radiotherapy (Fig 2).
Other NHL subtypes including T-cell lymphoma with pri-
mary retinal manifestation have been mostly reported as sin-
(D)
(A) (B) (C)
(E)
a
b
c
Fig 1. A 72-year-old female with a 17-month history of recurrent posterior uveitis of both eyes. No response to steroids. (A) Fundoscopy of the
left eye – diffuse orange-yellow retinal infiltrates. (B) Fluorescein angiography of the retina shows the typical variegated hyper- and hypopigmen-
tation (‘leopard skin’ appearance). (C) Intraocular vitrectomy sample stained with MGG shows an aggregate of large atypical lymphocytes with
some background macrophages (objective 60x); (D) CD79a+ B-cells are the dominant infiltrating cell population (objective 60x); (E) Allele-speci-
fic polymerase chain reaction with melting curve analysis for MYD88 mutation. Wild-type T 53°C, MYD88 L265P 61°C; Positive control (a),
patient DNA with (b) and without (c) WT-suppressing LNA. Diagnosis: vitreoretinal B-cell Lymphoma (VRL). Staging: concurrent central ner-
vous system disease. Treatment: Intrathecal and systemic R-CHOP with methotrexate. The patient succumbed to CNSL within one year of VRL
diagnosis.
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gle case reports (Ponzoni et al, 2002; Coupland et al, 2005c).
The few cases of T-VRL reported to date have shown a less
aggressive course compared to B-VRL (Coupland & Damato,
2008).
Secondary intraocular involvement by systemic lym-
phoma is relatively rare, and the disease is usually confined
to the choroid. The most common subtype is systemic
DLBCL (Coupland & Damato, 2008) but secondary infil-
tration of the eye by other B-NHL subtypes include
chronic lymphocytic leukaemia (Coupland et al, 2001),
plasma cell neoplasms (Fung et al, 2005) and, rarely, Bur-
kitt lymphoma (Payne et al, 1971; Wysenbeek et al, 1987)
as well as intravascular large B-cell lymphoma (Mudhar
et al, 2007). A peculiar phenomenon is the increased risk
for secondary vitreoretinal or CNS involvement by DLBCL
of the testis, another immune-privileged site, which shares
many features with PVRL and PCNSL, including predomi-
nance of the ABC type, common loss of HLA class I and
II expression and common MYD88 mutations (Riemersma
et al, 2000; Kraan et al, 2013). Of interest, joint MYD88
L265P mutations, indicating a common clonal origin, were
identified in two cases of VRL with a history of testicular
lymphoma in our recent VRL series (Bonzheim et al,
2015).
Epidemiology
The true incidence of PVRL is unknown because no central
database exists yet for this rare disease: hopefully, this major
deficiency will be overcome soon through the efforts of ‘The
American Joint Committee on Cancer Ophthalmic Oncology
Task Force’, who are presently establishing an international
multicentre VRL registry. It can be confidently stated that
PVRL is one of the rarest primary ocular tumours: a 20-year
retrospective study at a large Canadian hospital estimated the
incidence of VRL in British Columbia to be between 0017-
0048/100,000 people between the years 1990 and 2010
(Levasseur et al, 2013). Better data exist for PCNSL: the Cen-
tral Brain Tumor Registry of the United States published the
incidence of PCNSL in the U.S. as 046 per 100 000 person-
years between 2004-2007 and 045 per 100 000 person-years
between 2005–2009. The incidence was higher in males
(054) than in females (039), with a male:female ratio of
138. Similar incidence rates have been published in Europe
(Phillips et al, 2014; Hoang-Xuan et al, 2015).
PVRL usually occurs in adults from the third to the eighth
decades of life, with the median age at diagnosis in these
patients being 63 years, with no gender prevalence (Grimm
et al, 2007). Whilst the most important risk factors for
FR1 FR2 FR3(D)
(A)
(B)
(C) (E)
Fig 2. A 45-year-old male, with a 4-month history of blurred vision of the right eye. No previous medical history. Non-smoker. (A) Fundoscopy
– creamy choroidal infiltrates also close to the macula (arrow). (B) Optical Coherence Tomography (OCT) demonstrates a thickening of the
choroid with partial detachment of the retina (arrow). (C) Intraocular biopsy stained with May-Gr€unwald-Giemsa shows small atypical lympho-
cytes with some scattered background erythrocytes (objective 60x); (D) CD79a+ B-cells are the dominant cell population (objective 40x); (E)
IGH-polymerase chain reaction electrophoresis gel with bands at 310, 260 and 120 base pairs (FR1, FR2 and FR3, respectively). Diagnosis: pri-
mary choroidal ‘Extranodal Marginal Zone B-cell Lymphoma’ (EMZL). Staging investigations: no systemic or CNS disease. Treatment: low-dose
radiotherapy with good response.
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PCNSL are human immunodeficiency virus (HIV) status and
EBV infection status (Phillips et al, 2014), there are no other
known risk factors for PVRL.
Clinical features of VRL
Clinical presentation of VRL varies largely according to the
involved ocular structures and to the presence or absence of
concomitant brain and/or meningeal disease. Ocular symp-
toms are usually the only expression of disease in patients
with PVRL. Most of these patients have good performance
status, with a history of a prior malignancy in 10–15% of
cases (Hoang-Xuan et al, 2015).
The mean duration of PVRL symptoms prior to diagnosis
is 6 months, but, in some cases, symptoms precede diagnosis
by 2–3 years. The most common presenting symptoms are
non-specific, and include blurred vision in 40–50% of
patients, decreased visual acuity in 25–30% and floaters in
20–25%. Signs and symptoms of PRVL may mimic other
intraocular conditions, such as uveitis, thus making PVRL a
‘masquerade’ syndrome (AlQahtani et al, 2014). Bilateral
ocular involvement is common, occurring in 60–90% of
patients, but may appear clinically as unilateral involvement
due to uneven distribution of disease. CSF dissemination is
detected during staging workup in only 10–15% of cases
(Grimm et al, 2007).
Patients’ characteristics and clinical presentation do not
differ greatly between patients with PVRL and patients with
concomitant brain and ocular lymphoma. Median age and
gender distribution are the same, whereas performance status
is usually poorer in the latter group (Hoang-Xuan et al,
2015). Ocular symptoms are similar to those above reported
for PVRL patients, and can be concomitant to other neuro-
logical symptoms or precede the onset of brain lesions by
weeks or months, and sometimes years. The most commonly
associated neurological symptoms, which often span weeks to
months, are focal deficits, personality changes and increased
intracranial pressure: behavioural/cognitive changes in 25-
30% of cases, hemiparesis in 10-15%, headache in 10-15%,
aphasia in 10-15%, seizure in 5%, ataxia in 4% (Ferreri et al,
2002; Hoang-Xuan et al, 2015). Patients with ocular symp-
toms and asymptomatic brain disease are uncommon (3% of
cases) (Grimm et al, 2008). The average duration of symp-
toms prior to diagnosis is usually shorter than that reported
for PVRL (3 months). CSF infiltration is detected in 20-25%
during staging in patents with concomitant ocular and cere-
bral disease.
Diagnosis of VRL
Ophthalmological examination in VRL frequently demon-
strates the presence of vitritis, usually in association with
infiltrates of the retina and the retinal pigment epithelium,
sometimes giving the characteristic ‘leopard skin’ pigmenta-
tion (Fig 1) on fundoscopy and fluorescein angiography
(Fardeau et al, 2009), whereas alterations in the anterior seg-
ment of the eye are usually absent (Coupland & Damato,
2008; Chan & Sen, 2013; Sagoo et al, 2014). Recently, there
has been an interest in the autofluorescence findings in VRL
patients, with a granular pattern in autofluorescence being
suggestive of VRL (Egawa et al, 2014). Optical Coherence
Tomography has also been described as being informative in
VRL, with the visualization of nodular hyper-reflective
lesions in the retinal pigment epithelium corresponding to
lymphomatous cell deposition (Fardeau et al, 2009; Egawa
et al, 2014).
In patients with suspected concomitant ocular and cerebral
lymphoma, Contrast-enhanced cranial magnetic resonance
imaging (MRI) is the best imaging modality for assessing the
cerebral disease (Kuker et al, 2005; Hoang-Xuan et al, 2015).
Lesions are often isointense to hypointense on T2-weighted
MRI, with variable surrounding oedema and a homogeneous
and strong pattern of enhancement. In patients where MRI is
a contraindication, contrast-enhanced cranial computerized
tomography (CT) scans are recommended.
Although clinical examination and imaging procedures
often lead to a high suspicion of lymphoma, VRL frequently
mimics chronic posterior uveitis, including an initial response
to steroids. As a classical ‘masquerade syndrome’, VRL hence
requires diagnostic confirmation through invasive procedures
providing morphological, phenotypical and/or molecular evi-
dence for malignancy. Important differential diagnoses,
including fungal or bacterial endophthalmitis, sarcoidosis as
well as ocular syphilis and tuberculosis, need to be excluded
with special stains, cultures or molecular techniques.
In cases with concomitant CNS involvement, a positive
CSF examination or stereotactic brain biopsy may obviate
the need for intraocular biopsy. The standard approach to
diagnosis of PVRL is vitrectomy or vitreous aspirate biopsy.
In case this approach does not render a diagnosis, subretinal
aspirate biopsy or chorioretinal biopsy or of other intraocu-
lar structures may be used (Coupland, 2012). For a detailed
review of the surgical procedures, the reader is referred to
the ophthalmological literature. The aspirated material can
be used for cytological examination, immunocytochemistry,
flow cytometry, molecular examinations and determination
of cytokine levels. Therefore, an adequate triage system to
maximize the use of the limited material for the different
techniques should be in place in the pathology laboratory,
which ideally should be experienced in handling these sam-
ples. Pre-analytical conditions are of major importance.
Cytological material should either be worked within an hour
after aspiration, or alternatively put either into culture med-
ium or a mild fixative, such as HOPE (Hepes-glutamic acid
buffer-mediated organic solvent protection effect) solution,
which preserves cytological detail, as well as immunoreactiv-
ity and nucleic acids (Coupland, 2012). Cytological speci-
mens are usually prepared with the cytospin technique;
alternatively, the cell-block technique can be employed for
cell-rich specimens.
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Cytology and immunocytochemistry
Cytological examination reveals the presence of large, atypical
lymphoid cells with increased nuclear/cytoplasmic ratio,
basophilic cytoplasm and irregular nuclei with one to several
nucleoli in cases of VRL. However, large numbers of reactive
lymphocytes, poor preservation of cytological detail due to
degenerative changes and necrosis, and paucicellular aspirates
due to limited involvement of the vitreous or an antecedent
steroid therapy often preclude a diagnosis of malignancy
based only on morphology. Furthermore, atypical large cells
may also occur in reactive conditions, such as acute viral
infection. The reported rates of sensitivity and specificity of
cytology for the diagnosis of VRL vary widely, but cytology
alone is able to confirm VRL in 45–60% of cases, and false
positive results are considered rare (Davis et al, 2005; Wit-
tenberg et al, 2008; Kimura et al, 2012).
Immunocytochemistry is a valuable tool for confirming a
diagnosis of VRL, with a predominance of large cells express-
ing pan B-cell markers such as CD20, PAX5 and CD79a.
Alternatively, multicolour flow cytometry has been success-
fully employed for phenotyping of vitreal aspirates, with a
reported sensitivity of 82% and 100% specificity (Missotten
et al, 2013). Again, however, poor cellular preservation and
abundant reactive T-cells may limit the diagnostic yield
(Davis et al, 2012).
Molecular diagnosis of VRL
Molecular examination of vitreous specimens is a valuable
tool to confirm a diagnosis of lymphoma, and the applica-
tion of modern PCR techniques has reduced the necessary
amount of material considerably. Identification of clonal
immunoglobulin gene rearrangements using consensus pri-
mer sets such as those developed by the BIOMED-2 consor-
tium is a mainstay in VRL diagnosis. The sensitivity of
clonality studies ranges between 65% and 95%, depending
on the choice of primer sets and quality of material (Coup-
land et al, 2003, 2005b; Merle-Beral et al, 2004; Baehring
et al, 2005; Wang et al, 2011; Kimura et al, 2012). Depend-
ing on the number of primer sets used – which can be lim-
ited by the available material – VRL of DLBCL type may also
yield false negative results due to somatic hypermutation
abrogating primer binding. On the other hand, due to the
unique situation of the eye as immune-privileged site,
inflammatory conditions can also result in oligoclonal or
even clonal expansions of lymphocytes and may lead to false
positive results, especially in cases with low cellularity (Sugita
et al, 2009; Bonzheim et al, 2015). In order to avoid misdiag-
nosis of minor clonal expansions as evidence for lymphoma,
all tests should be run in duplicate to confirm the presence
of a dominant clone, and results should be interpreted with
caution and only in the context of clinical and morphological
findings. Determination of clonality is especially valuable for
cases in which suspected intraocular dissemination or relapse
of PCNSL or systemic lymphoma can be confirmed by prov-
ing or disproving clonal relationship.
In order to increase the diagnostic yield of vitreous speci-
mens, we recently made use of the common occurrence of
MYD88 mutations in PCNSL, identified in 50–70% of cases.
Arguing that VRL, as a subtype of PCNSL, should show a
similar high frequency, we used a sensitive allele-specific PCR
for the most common mutation MYD88 L265P, and conven-
tional sequencing for exons 3 and 4 in a large series of archi-
val vitreous specimens from two institutions (Bonzheim
et al, 2015). We detected MYD88 mutations, in 20/28 sam-
ples of confirmed VRL, with the canonical L265P in all but a
single case (Fig 1). None of the cases classified as reactive
was positive for MYD88 mutations. Importantly, this
approach confirmed a diagnosis of VRL in 6 cases initially
diagnosed as either only suspicious for lymphoma or reactive
based on cytology, immunocytochemistry and clonality anal-
ysis, thus increasing the sensitivity of vitreous biopsy for
VRL diagnosis from 62% to 90%. Although these findings
need to be confirmed in a prospective manner, mutational
analysis using sensitive techniques, such as allele-specific PCR
or next generation sequencing using mutation-specific panels,
will probably provide a valuable additional tool for the diag-
nosis and, perhaps, the follow-up of VRL.
Determination of cytokine levels
Some centres advocate the use of measurement of cytokine
levels within ocular fluids – i.e. aqueous humor and the vit-
reous – to provide diagnostic evidence in addition to cytol-
ogy for the presence/absence of PVRL (Chan et al, 1995;
Merle-Beral et al, 2004; Cassoux et al, 2007; Saleh et al,
2012; Fisson et al, 2013; Raja et al, 2013; Mehta et al, 2015).
In particular, these centres measure the levels of interleukin
(IL) 10 and IL6 and then compare their ratio: a high level of
IL10 in pure vitreous or aqueous humor samples, or an
IL10:IL6 ratio greater than 1 in diluted or undiluted samples,
is considered indirect evidence supporting the diagnosis of
PVRL. The techniques used to measure the IL10 and IL6
levels include enzyme-linked immunosorbent assay (ELISA)
and multiplex-based cytometric bead array. The exact cutoff
for the IL10 concentration or IL10:IL6 ratio may vary
between laboratories, mainly due to differences in the meth-
ods applied, the conditions of sample harvesting and storage,
techniques, and manufacturers of equipment and supplies, as
well as the dilution (known or unknown) of the vitreous
samples and the laboratory’s own experience. Interleukin
levels within intraocular fluids have also been proposed and
used with some success to monitor response of PVRL under
therapy (Saleh et al, 2012; Raja et al, 2013). In larger series,
the sensitivity of IL10 measurements and/or the IL10:IL6
ratio in VRL is 80–90%, with virtually no false positives
reported, making cytokine determination a valuable addi-
tional diagnostic tool (Chan et al, 1995; Merle-Beral et al,
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2004; Cassoux et al, 2007; Saleh et al, 2012; Fisson et al,
2013; Raja et al, 2013; Mehta et al, 2015).
Our approach
In our institutions, we immediately work up the freshly
received vitrectomy specimens, preparing cytospins for cyto-
logical and immunocytochemical examinations with a limited
panel of antibodies, including at least CD20 and CD3. The
remainder of the aspirate is used for molecular studies,
including clonality analysis using BIOMED-2 primers and
MYD88 mutational analysis with an allele-specific PCR. Of
note, the results of clonality analysis are interpreted only in
the context of other parameters in order to avoid overinter-
pretation of pseudoclonal bands.
Staging examinations
By definition, PVRL is a stage I disease, irrespective of con-
comitant CNS involvement. Staging in PVRL has two objec-
tives: to determine the presence and extent of CNS
involvement, and to rule out systemic lymphoma (Hoang-
Xuan et al, 2015), which is rare in patients presenting with
VRL. As mentioned above, neuroimaging with contrasted
MRI is the method of choice for determining cerebral disease
(Kuker et al, 2005; Hoang-Xuan et al, 2015). In addition, a
cytological examination of CSF, potentially complemented by
clonality analysis is required, but one has to keep in mind
that cytology may be difficult to assess and clonality analysis
can be misleading in specimens with low cellularity. Systemic
studies include whole body fluorodeoxy-glucose positron
emission tomography (FDG-PET) and testicular sonography,
given the propensity of testicular lymphoma for intraocular
and CNS dissemination. Complete physical and neurological
examination, bone marrow biopsy, standard laboratory tests
and liver, kidney and cardiac function tests and HIV serology
are all included in the standard workup of PVRL patients.
Treatment
Primary vitreoretinal lymphoma
From a clinical standpoint, a variable proportion of patients
with PVRL experience CNS dissemination, whereas the dis-
ease remains confined to the eyes for months or years in
others. The goal of the treatment of PVRL is cure and vision
retention, which can be achieved by controlling intraocular
disease and preventing CNS dissemination. The level of evi-
dence supporting therapeutic decisions in PVRL is very low
because related literature is sparse and fragmentary, and
prospective trials exclusively focused on PVRL do not exist.
The main open and often debated question regards the dis-
tinction of VRL patients who can be managed with ocular
treatment alone (e.g. using intravitreal methotrexate (MTX),
intravitreal Rituximab, and/or binocular external beam radia-
tion – see also below) (Smith et al, 2002; Helbig et al, 2003;
Frenkel et al, 2008; Raja et al, 2013; Larkin et al, 2014) and
those patients who need systemic chemotherapy. Accord-
ingly, some investigators have reviewed multicentre retro-
spective series of patients with primary or secondary
intraocular lymphoma with the aim to distinguish parame-
ters predicting CNS dissemination (Grimm et al, 2007, 2008;
Riemens et al, 2015). Unfortunately, reported studies display
several selection and interpretation biases, and predicting
parameters remain to be defined. The major criticisms of
reported studies are the lack of central pathology review,
which is a relevant drawback as the modest diagnostic effi-
cacy of vitrectomy, and the confounding factor determined
by the specialty of investigators performing case collection
(Ferreri, 2015). In fact, the 3-year CNS relapse rate was 60%
in the series collected by neuro-oncologists (Grimm et al,
2007), and 36% in the series collected by ophthalmologists
(Riemens et al, 2015). Other limitations of these studies
regard the inclusion of small patient subgroups receiving var-
ied treatments being analysed together in an arbitrary way,
and the long period of study, during which diagnosis and
treatment of CNS lymphomas changed greatly.
Albeit with the above-mentioned biases, large retrospective
studies seem to suggest that patients with newly diagnosed
PVRL should be treated with local strategies, keeping the so-
called ‘extensive treatments’ for brain relapses (Grimm et al,
2007; Riemens et al, 2015). This seems to be a suitable
approach because local strategies are associated with negligi-
ble systemic toxicity and, in contrast to intravenous high-
dose MTX, intravitreal chemotherapy results in prolonged
therapeutic drug concentrations and ocular irradiation allows
better local control (Ferreri et al, 2002). In fact, patients
receiving ocular treatment alone show good local disease
control, with an intraocular relapse rate of only 13% at a
median follow-up of 4 years (Riemens et al, 2015). However,
the major concern when managing PVRL with local treat-
ment alone remains the risk of CNS dissemination, which is
a devastating event that occurs in half of patients (Grimm
et al, 2007), resulting in a 4-year overall survival (OS) of
32%. Conversely, patients with PVRL receiving systemic
chemotherapy had a CNS relapse rate of 43%, but the
reported 4-year OS is 85% (Riemens et al, 2015). These data
seem to favour ‘extensive treatments’ over ‘ocular treat-
ments’. The combination of both treatments has not been
adequately assessed because ocular therapies were often com-
bined with suboptimal systemic treatments, with consequent
disappointing outcome (Riemens et al, 2015).
In summary, available studies suggest that some patients
with PVRL can be safely treated with local treatment alone,
while other patients should be treated with systemic
chemotherapy (Smith et al, 2002; Helbig et al, 2003; Frenkel
et al, 2008; Raja et al, 2013; Larkin et al, 2014). Unfortu-
nately, efforts to distinguish the best candidates for each
strategy remain unfruitful owing to relevant selection and
interpretation biases, and international efforts aimed to
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distinguish predictors of CNS dissemination are needed (Fer-
reri, 2015). In the meantime, both high-dose MTX-based
chemotherapy (with or without whole brain radiotherapy
[WBRT]) and ocular therapy (intravitreal chemotherapy or
ocular radiotherapy) are acceptable strategies according to
European guidelines (Hoang-Xuan et al, 2015).
At our institutions, we usually treat patients with cytologi-
cally confirmed diagnosis of PVRL without brain disease with
the same approach used for PCNSL in general (see next sec-
tion). This is aimed to prevent the devastating event of cere-
bral and/or meningeal dissemination.
PCNSL with ocular involvement
There are no reasons to treat PCNSL patients with ocular
disease differently than the other PCNSL patients (Hoang-
Xuan et al, 2015). Typically, patients with PCNSL are treated
with high-dose MTX-based polychemotherapy followed by
consolidative WBRT or, alternatively, with either autologous
stem cell transplantation (Kasenda et al, 2012) or non-mye-
loablative cytarabine-etoposide chemotherapy (Rubenstein
et al, 2013b). Intrathecal drug delivery is less commonly
used, and indeed has not been employed in recently reported
(Morris et al, 2013; Rubenstein et al, 2013b; Omuro et al,
2015a) or on-going trials (Ferreri et al, 2013). It is worth
noting that patients with intraocular disease represent 5–10%
of considered cases in prospective trials on PCNSL: these
results have not been reported separately and, consequently,
it is not possible to draw definitive conclusions on the role
and therapeutic efficacy of each of these strategies in the sub-
group of patients with ocular disease (Ferreri et al, 2009;
Morris et al, 2013; Omuro et al, 2015b).
The eye is a chemotherapy sanctuary where PCNSL
tumour cells can grow undisturbed, and chemotherapy effi-
cacy depends on intraocular pharmacokinetics, which are not
well understood for most cytostatics. Systemic administration
of MTX and cytarabine can yield therapeutic drug levels in
the intraocular fluids and clinical responses have been docu-
mented; however, drug concentrations in vitreous humor are
unpredictable and intraocular relapse is common (Batchelor
et al, 2003). Although the inclusion of both eyes in the irra-
diation volume seems to improve disease control (Ferreri
et al, 2002; Hoang-Xuan et al, 2015), many researchers are
concerned by the risk of lymphoma cells persistence in the
eyes, with the consequent increased risk of tumour relapse.
Consequently, a benefit from the addition of direct intravit-
real injection of cytostatics has been hypothesized, and a
large retrospective study has suggested that this strategy is
associated with improved progression-free survival (Grimm
et al, 2008), but its effect on OS remains to be defined.
Intravitreal MTX is highly effective but does not affect OS,
and is associated with important side effects in 73% of eyes
and significant deterioration of visual acuity in 27% of
patients (Smith et al, 2002; Frenkel et al, 2008). In fact,
intravitreal chemotherapy has been associated with cataract
in 73% of treated eyes, corneal epitheliopathy in 58%, macu-
lopathy in 42% and less commonly with vitreous haemor-
rhage (8%), optic atrophy (4%) and sterile endophthalmitis
(4%).
Another agent administered in patients with PVRL, with
and without any evidence of concomitant cerebral disease,
includes intravitreal rituximab, an anti-CD20 monoclonal
antibody, either alone or in combination with intravitreal
MTX. Most data regarding the efficacy of rituximab in treat-
ing PVRL currently comes from case reports and a few retro-
spective case series (Itty & Pulido, 2009; Vosganian et al,
2011; Hashida et al, 2012; Turaka et al, 2012). Although
these authors suggest that rituximab is safe and efficacious in
PVRL, these results do further emphasize the need for
prospective clinical trials in competitive treatments for this
aggressive disease.
On-going prospective trials exclusively focused on PVRL
patients do not exist, while some patients with PCNSL and
intraocular disease are being enrolled in a few on-going
trials addressing new drugs. In particular, based on the high
rates of ABC-DLBCL, CD79B and MYD88 mutations in
this population, ibrutinib (NCT02542514; NCT02623010;
NCT02315326), lenalidomide (NCT01542918; NCT01956695)
and pomalidomide (NCT01722305), are being tested as main-
tenance or salvage monotherapy in PCNSL. Other drugs
exploiting involved molecular pathways are being addressed in
prospective trials, in particular, buparlisib (NCT02301364), a
pan- phosphoinositide 3-kinase inhibitor. It is very hard to
imagine the impact these trials could have on the management
of PVRL, as only a minority of enrolled patients will be
affected by this disorder. Nevertheless, international coopera-
tion to perform this type of study should be strongly encour-
aged to offer trial participation to most PVRL patients.
Prognosis and prognostic markers of PVRL
To date, there is very little data concerning pathological
biomarkers that predict the prognosis of PVRL. For PCNSL,
the International Extranodal Lymphoma Study Group
(IELSG) has identified five clinical variables that correlate
with prognosis, three of which are shared with systemic
NHL: elevated lactate dehydrogenase (LDH), age greater than
60 years, and an Eastern Cooperative Group performance
status greater than 1; parameters specific to PCNSL include
elevated CSF protein as well as tumour location within the
deep regions of the brain (periventricular, basal ganglia,
brainstem and/or cerebellum). The presence of 0–1, 2–3, or
4–5 adverse risk factors correlates with 2-year survival rates
of 80%, 48% or 15%, respectively (Ferreri et al, 2003). While
the IELSG considered age 60 years to be the cut-off point
above which prognosis declines, the Memorial Sloan-Ketter-
ing prognostic index employs an age cut-off point of
50 years (Abrey et al, 2006). These prognostic models can
only be used in PVRL if there is concomitant cerebral dis-
ease. A clinical prognostic index for PVRL alone has yet not
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been devised, but could be an output of the above-men-
tioned international PVRL registry.
Conclusion
Though no standardized recommendations exist for the diag-
nosis and treatment of PVRL, significant advances have been
made in the field in the last decades regarding earlier detec-
tion of the disease, both clinically and using novel pathologi-
cal tests, as well as in the efficacy testing of combined
radiotherapy and chemotherapy. The advent of biologicals,
such as rituximab, creates hope in the community for a tar-
geted and efficacious therapy. Multicentre collaborative inter-
national registries and carefully designed clinical trials with
associated translational research are the only way forward to
better understand the pathogenesis of PVRL, determine the
true relative efficacy and tolerability of available therapies
and to identify abnormal pathways that could lead to the use
of new target agents.
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